Novacyt : Follow-up chart relating to the OCABSA agreement 26th September 2019
September 26, 2019 at 06:13 am EDT
Share
OCABSA Agreement - Follow-up Chart - 25 September 2019
Tranche 1
Issuance date of OCABSA
25/04/2019
Exercise date of BEOCABSA
25/04/2019
Number of OCA (notes convertible into shares)
874
Number of BSA (subscription warrants)
2,979,544
Date
Nb
Shares issued
BSA exercised
OCA converted
26/04/2019
1
15,625
02/05/2019
7
116,666
14/05/2019
14
250,000
14/05/2019
19
339,285
16/05/2019
11
229,166
16/05/2019
16
333,333
12/06/2019
5
138,888
18/06/2019
17
472,222
19/06/2019
22
611,111
21/06/2019
7
194,444
24/06/2019
8
222,222
28/06/2019
2
62,500
08/07/2019
1
35,714
15/07/2019
30
1,071,428
16/07/2019
10
357,142
01/08/2019
100
3,753,753
06/08/2019
51
1,914,414
12/08/2019
51
1,912,500
23/08/2019
40
1,500,000
28/08/2019
60
2,250,000
11/09/2019
20
750,000
12/09/2019
18
675,000
18/09/2019
12
450,000
23/09/2019
10
375,000
25/09/2019
38
1,425,000
Outstanding OCA
304
Outstanding BSA
2,979,544
Number of shares created
19,455,413
Total number of shares issued under the OCABSA agreement :
19,455,413
Attachments
Original document
Permalink
Disclaimer
Novacyt SA published this content on 26 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 September 2019 10:12:02 UTC
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.